1 rich Libsyn https://www.libsyn.com 300 600 🎯 Lower. Further. Better: The New LDL Frontier The New England Journal of Medicine has now given us randomized trial evidence for a question long guided more by extrapolation than by direct proof: in patients with established atherosclerotic cardiovascular disease, targeting LDL cholesterol to &amp;lt;55 mg/dL beat a target of &amp;lt;70 mg/dL over 3 years. In Ez-PAVE, the primary end point occurred in 6.6% vs 9.7%, with a hazard ratio of 0.67, supporting a more intensive LDL strategy for secondary prevention. &amp;nbsp; Elegant trial, practical message: when risk is high, lower may truly be better. 🫀📉🎯 Journal: New England Journal of Medicine. Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity! http://www.MasterMedFacts.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/40705795/height/300/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="300" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/200367470